Gossamer Bio Announces Appointment of Steven D. Nathan to its Board of Directors
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it has granted stock options to Bob Smith, Gossamer’s newly appointed Chief Commercial Officer. The Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 4, 2023, to Mr. Smith of a stock option to purchase 1,500,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The award was granted as an inducement material to Mr. Smith entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio Announces Appointment of John Quisel to its Board of Directors
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023